Hepatitis b core protein allosteric modulators

A compound of Formula 7:

• or a pharmaceutically acceptable salt thereof,
• wherein
• Y is S(O)y, wherein y is 2;
• each of Rm and Rm′ independently is selected from the group consisting of H, halogen, C1-6 alkyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), C2-6 alkenyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), NR′R″, and hydroxyl;
• Rc is H or C1-6 alkyl;
• each of R4, R5, R6, R7, R8, R9, and R10 independently is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkynyl, C2-6 alkenyl, halogen, hydroxyl, nitro, cyano, and NR′R″;
• R78 is selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, NR′R″, —C(O)—C1-6 alkyl, —C(O)—C1-6 alkoxy, phenyl, heteroaryl, C3-6 cycloalkyl, —S(O)w-C1-6 alkyl (where w is 1, 2 or 3), —S(O)w-NR′R″ (where w is 1, 2 or 3), and —NR′—S(O)w, (where w is 1, 2 or 3);
• R79 is selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, NR′R″, —C(O)—C1-6 alkyl, —C(O)—C1-6 alkoxy, phenyl, heteroaryl, C3-6 cycloalkyl, —S(O)w-C1-6 alkyl (where w is 1, 2 or 3), —S(O)w-NR′R″ (where w is 1, 2 or 3), and —NR′—S(O)w, (where w is 1, 2 or 3);
• each R′ independently is selected from the group consisting of H, methyl, ethyl, and propyl;
• each R″ is independently selected from H, methyl, ethyl, propyl, butyl, —C(O)-methyl and —C(O)-ethyl, or R′ and R″ taken together with the nitrogen to which they are attached may form a 4-6 membered heterocycle;
• and
• for each occurrence, C1-6 alkyl may be optionally substituted with one, two, or three halogens.